Teva fêted in corporate-mad Switzerland
Teva Pharmaceutical Industries, the Israeli generic drug company, this week became the latest debut issuer to enjoy the strength of Swiss franc buyers’ desire for corporate bonds.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts